On June 26, 2024, Aclarion, Inc., a healthcare technology company, announced that its Nociscan product has secured initial payer coverage by AXA, a major private medical insurance provider in the U.K., specifically for the greater London area. This coverage by AXA, which is the second-largest provider of private medical insurance in the U.K., represents a significant milestone for Aclarion as it is the first insurance company to approve payment for Nociscan. The London Clinic, a prominent independent hospital in the U.K., has adopted Nociscan as a decision support tool for diagnosing and treating chronic low back pain patients. The AXA coverage decision is expected to increase access to Nociscan for insured patients, marking a crucial step in Aclarion's commercialization efforts and potentially leading to wider adoption as other insurers may follow AXA's lead. Aclarion leverages Magnetic Resonance Spectroscopy and proprietary algorithms to help physicians identify the sources of chronic low back pain, aiming to improve treatment outcomes.

On June 26, 2024, Aclarion, Inc., a healthcare technology company, announced that its Nociscan product has secured initial payer coverage by AXA, a major private medical insurance provider in the U.K., specifically for the greater London area. This coverage by AXA, which is the second-largest provider of private medical insurance in the U.K., represents a significant milestone for Aclarion as it is the first insurance company to approve payment for Nociscan. The London Clinic, a prominent independent hospital in the U.K., has adopted Nociscan as a decision support tool for diagnosing and treating chronic low back pain patients. The AXA coverage decision is expected to increase access to Nociscan for insured patients, marking a crucial step in Aclarion's commercialization efforts and potentially leading to wider adoption as other insurers may follow AXA's lead. Aclarion leverages Magnetic Resonance Spectroscopy and proprietary algorithms to help physicians identify the sources of chronic low back pain, aiming to improve treatment outcomes.